Axogen Launches New Product to Aid Nerve Healing: Avive+ Soft Tissue Matrix
Portfolio Pulse from Benzinga Newsdesk
Axogen, Inc. (NASDAQ:AXGN) has launched a new product, Avive+ Soft Tissue Matrix, designed to aid in nerve healing. This product is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. The product complies with FDA regulations and aims to address a significant need in the $800 million nerve protection market.
June 24, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axogen has launched Avive+ Soft Tissue Matrix, a new product designed to aid in nerve healing. This product is expected to enhance Axogen's portfolio and address a significant need in the $800 million nerve protection market.
The launch of Avive+ Soft Tissue Matrix is likely to positively impact Axogen's stock price in the short term. The product addresses a significant need in the nerve protection market, which is valued at $800 million. This innovation enhances Axogen's portfolio and aligns with the company's mission to provide comprehensive solutions for nerve protection.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100